Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma

Conditions:   Central Nervous System B-Cell Non-Hodgkin Lymphoma;   Recurrent Central Nervous System Lymphoma;   Refractory Central Nervous System Lymphoma Interventions:   Drug: Ibrutinib;   Biological: Nivolumab Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials